🔗 Share this article

The first new treatments for gonorrhoea in a generation are being hailed as a "significant breakthrough" in the effort against drug-resistant strains of the bacteria, according to researchers.

An International Health Concern

The sexually transmitted infection are on the rise around the world, with data suggesting in excess of 82 million infections annually. Notably increased rates are seen in Africa and countries within the WHO's Western Pacific region, which includes Mongolia and China to New Zealand. Within England, cases have reached a historical peak, while rates across Europe in 2023 were three times higher compared to figures for 2014.

“The authorization of novel therapies for gonorrhoea is an significant and necessary advancement in the context of growing infection rates, increasing antimicrobial resistance and the extremely scarce treatment choices at this time.”

Public health authorities are particularly alarmed about the increase in drug-resistant strains. The WHO has designated it as a "critical concern". A tracking program found that the effectiveness of primary antibiotics like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Two New Treatment Options Gain Clearance

Zoliflodacin, alternatively called Nuzolvence, was authorized by the US Food and Drug Administration in December for use against gonorrhoea. This infection can lead to serious health problems, including infertility. Researchers anticipate that specific application of this new drug will help delay the development of resistance.

Another new antibiotic, originating from the drugmaker GlaxoSmithKline, also received approval in the same week. This medication, which is also used to treat UTIs, was proven in research to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Partnership

Zoliflodacin stemmed from a innovative non-profit model for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the drug firm its industry partner to see it through.

“This authorization represents a major breakthrough in the management of highly resistant gonorrhoea, which until now has been staying ahead of antibiotic development.”

Testing Results and Worldwide Availability

Based on data released by a major medical journal, zoliflodacin cured more than 90% of uncomplicated infections. This puts it on an comparable level with the current standard treatment, which involves two antibiotics. The trial enrolled nearly 1,000 patients from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its development partnership, the non-profit has the authority to license and sell the drug in a wide range of regions with limited resources.

Doctors on the front lines have shared positive views. Having a easy-to-administer therapy of this kind is seen as a "critical tool" for gonorrhoea control. This is deemed crucial to reduce the burden of the illness for individuals and to prevent the spread of extremely resistant gonorrhoea around the world.